Connect
MJA

Risks and realities of single vial antivenom recommendations for envenoming by Australian elapid snakes

Scott A Weinstein, Peter J Mirtschin and Julian White
Med J Aust 2020; 213 (1): . || doi: 10.5694/mja2.50651
Published online: 6 July 2020

In reply: We note incorrect assertions in the comments by Isbister and colleagues regarding our article on single vial antivenom recommendations for elapid envenoming in Australia.1

  • Scott A Weinstein1
  • Peter J Mirtschin2
  • Julian White1

  • 1 Women's and Children's Hospital Adelaide, Adelaide, SA
  • 2 Venom Science, Adelaide, SA

Correspondence: venfraction@yahoo.com

Competing interests:

Julian White provides advice to Seqirus, manufacturer of antivenoms used in Australia, as part of a contract between his employing hospital and Seqirus. He occasionally receives travel support to attend toxinology meetings from Seqirus. However, he does not receive any financial remuneration or other compensation from Seqirus, and Seqirus has no role, input or influence on any of his reports, clinical practice or comments. He also provided an invited opinion in the referenced coronial cases. Peter Mirtschin provided independent commentary included in the coronial reports and is owner of Venom Supplies in the Barossa Valley, SA, a business that is leased to others; this business occasionally conducts business with Seqirus, but he has no input into, and does not receive any financial remuneration or other compensation from, Seqirus.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.